Outcomes of Daily Dose versus Part-daily Dose Treatment for Lung Tuberculosis: A Real-World Database Study in an Indonesian Hospital

William William, Purwantyastuti Ascobat, Instiaty Instiaty, Heidy Agustin


Background: a meta-analysis of randomized control trials (RCTs) on category I pulmonary tuberculosis (PTB) treatments showed that either part-daily (2RHZE/4R3H3) or daily dose (2RHZE/4RH) had the same failure and recurrence rates. However, the World Health Organization (WHO) concluded that the part-daily dose had higher failure and recurrence rates. Therefore, this study was conducted to compare the treatment outcomes between both regimens, whether daily dose regimen has a better treatment outcome than part-daily dose regimen, and the adverse effects between both regimens. Methods: this was an analytic cross-sectional study of patients at the Persahabatan General Hospital, over the period of January 2015-June 2018. Data were taken from medical records and supported by telephone interviews, each regimen group had 175 patients. Results: there were no significant differences for success rates (p=0.470), lost to follow up rates (p=0.659), failure rates (p=1.000), death rates (p=1.000), and adverse effects in the continuation phase (p=0.324) between the groups. There were, however, significant differences in cure rates (p < 0.001) and complete treatment rates (p<0.001) between the groups. Conclusion: the cure rate and complete treatment rate were found to be better for the part-daily than the daily doses. The success rate of both regimens were the same as Indonesia’s target (90%). In the continuation phase, there were no significant difference of adverse effects between both regimens.


Adverse effects; dose regimen; treatment outcomes; pulmonary tuberculosis


Anderson L, Baddeley A, Dean A, et al. Global tuberculosis report 2018. Geneva: WHO. 2018. p. 1-265.

Sutarjo US, Budijanto D, Kurniawan R, Yudianto, Hardhana B, Siswanti T. Profil kesehatan Indonesia 2017. Jakarta: KemKes RI. 2018:159-65.

Van Den Boogard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: Problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009;53(3):849-62.

Kazosi S, Clark J, Suhail AR. Intermittent versus daily pulmonary tuberculosis treatment regimens: A meta-analysis. Clin Med Res. 2015;13(3-4):117-38.

Subuh HM, Waworuntu W, Surya A, Armanda AJ, Lukitosari E, Isbaniah F dkk. Pengobatan pasien tuberkulosis. Jakarta: KemKes RI Dirjen P3L. 2017. p. 1-116.

Johnston JC, Campbell JR, Menzies D. Effect of intermittency on treatment outcome in pulmonary tuberculosis: An update systematic review and meta-analysis. Clin Infect Dis. 2017;xx(xx):1-20.

Schunemann H, Aung ST, Bonsu F, et al. Treatment of tuberculosis: Guidelines for treatment of drug-susceptible tuberculosis and patient care 2017 update. Geneva: WHO. 2017:1-56.

Suryanto AA, van den Broek J, Matta M, de Soldenhoff R, van der Werf. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia. Int J Tuberc lung Dis. 2008;12(2):174-9.

Bartacek A, Schutt D, Panosch B, Borek M. Comparison of a four-drugs fixed dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009;13(6):760-6.

Aseffa A, Chukwu JN, Vahedi M, Aguwa EN, Bedru A, Mebrahtu T. Efficacy and safety of ‘fixed dose’ versus ‘loose’ drug regimens for treatment of pulmonary tuberculosis in two high TB-burden African country: A randomized controlled trial. PLos One. 2016;11(6):1-13.

Lienhardt C, Cook SV, Burgos M, Edwards VY, Rigouts L, Anyo G. Efficacy and safety of a 4-drugs fixed dosed combination regimen compared with separate drugs for threatment of pulmonary tuberculosis: The study C randomized controlled trial. JAMA. 2011;305(14):1415-23.

Proano A, Bravard MA, Lopez JW, et al. Dynamics of cough frequency in adults undergoing treatment for pulmonary tuberculosis. Clin Infect Dis. 2017;64(9):1174-81.

Chan CY, Au-Yeang C, Yew WW, Hui M, Cheng AFB. Postantibiotic effects of antituberculosis agents alone and in combination. Antimicrob Agents Chemother. 2001;45(12):3631-34.

Gumbo T, Louie A, Deziel MR, et al. Concentration-dependant Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51(11):3781-8.

Gumbo T. Chemotheraphy of tuberculosis, Mycobacterum avium complex disease, and leprosy. In: Brunton LL, Chabner BA, Knollmann BJ, editors. Goodman & Gilman’s the Pharmacological Basis of Therapeutics 12nd ed. New York: McGraw-Hill Company. 2014:1363-81.

Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tuberculosis: A historical perspective. Ann Am Thorac Soc. 2015;12(12):1749-59.

Gravendeel JMT, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side effect, complaints and treatment results of a single-drug short course regimen with a four-drug fixed dose-combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis. 2003;83:186-6.

Full Text: PDF


  • There are currently no refbacks.